Optimized Application of 68Ga-Prostate-Specific Membrane Antigen-617 Whole-Body PET/CT and Pelvic PET/MR in Prostate Cancer Initial Diagnosis and Staging

Purpose: To analyze 68 Ga-PSMA-617 PET/CT or PET/MR and delayed images in patients diagnosed with suspicion of prostate cancer, to explore the optimal use for initial diagnosis staging cancer. Methods: Images from conventional scan by Ga-PSMA whole-body followed pelvic were retrospectively analyzed. Prostatic uptake was measured as SUVmax1 (conventional 1 h post injection) SUVmax2 (delayed 3 injection). Age, PSA levels, SUVmax compared between benign malignant cases. The correlation Diagnostic performance evaluated ROC analysis. Results: Fifty-six 41 cancers 15 lesions enrolled. Fifty-three had paired scans. tPSA, fPSA significantly different A good found SUVmax2. There significant difference group ( p = 0.001). superior diagnostic than SUVmax2, a sensitivity 85.4%, specificity 100% an AUC 0.956. combination nodal and/or distant metastases MR PI-RADS V2 score 100%. Delayed imaging 33 be redundant because these which can easily detected PET/CT. provided incremental value 8 at early-stage cancer based on precise anatomical localization changes lesion signal MR. Conclusion: Combined accurately differentiate diseases stage Whole-body is sufficient advanced Pelvic contributes accurate early Imaging about after injection most patients. ClinicalTrials.gov : NCT03756077. Registered 27 November 2018—Retrospectively registered, https://clinicaltrials.gov/show/NCT03756077 .